Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Parallel-Group, Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment

NCT07807059 is registered in ClinicalTrials.gov with Fujian Shengdi Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07807059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Parallel-Group, Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
September 9, 2026
Completion date
March 15, 2027
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatotic liver disease/steatohepatitis (masld/mash), overweight/obesity, type 2 diabetes mellitus